MULTICOV-AB

Project Image:
Title of the project:
MULTICOV-AB
Teasertext:
Having successfully established the MULTICOV-AB antibody binding assay, the Multiplex Immunoassays group at the NMI has now received funding from the Baden-Wurttemberg Ministry of Economic Affairs, Labour and Tourism to implement the assay in a wide variety of projects.
Start:
01.11.2020
End:
31.12.2022
Project leader:
Dr. Nicole Schneiderhan-Marra
Project funding:
  • BW Ministerium für Wirtschaft, Arbeit und Tourismus
Funding reference number:
3-4332.62-NMI/68
Text:

Having developed, validated and established the MULTICOV-AB assay as part of the CORESMA project, the Multiplex Immunoassays group has now received additional funding to enable its implementation in several projects. MULTICOV-AB, a multiplex immunoassay, allows the parallel testing of the individual immune response against different proteins or protein fragments of the novel SARS-CoV-2 virus and the widespread endemic coronaviruses NL63, OC43, 229E and HKU1. In this project, it is envisaged that MULTICOV-AB will be used for screening of infection/vaccination status within vulnerable populations (e.g. clinical staff, immunosuppressed individuals), as part of seroprevalence studies to assess the spread of SARS-CoV-2 throughout the population, and to assess humoral responses following vaccination.
Go back